Lisa C. Lindesmith
YOU?
Author Swipe
View article: Human Norovirus Epitope D Plasticity Allows Escape from Antibody Immunity without Loss of Capacity for Binding Cellular Ligands
Human Norovirus Epitope D Plasticity Allows Escape from Antibody Immunity without Loss of Capacity for Binding Cellular Ligands Open
Emergent strains of human norovirus seed pandemic waves of disease. These new strains have altered ligand binding and antigenicity characteristics. Study of viral variants isolated from immunosuppressed patients with long-term norovirus in…
View article: A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies
A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies Open
A GII.2 outbreak in an efficacy study of a bivalent virus-like particle norovirus vaccine, TAK-214, in healthy US adults provided an opportunity to examine GII.4 homotypic vs GII.2 heterotypic responses to vaccination and infection. Three …
View article: Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection
Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection Open
Nucleoside-modified mRNA-LNP vaccines have revolutionized vaccine development against infectious pathogens due to their ability to elicit potent humoral and cellular immune responses. In this article, we present the results of the first no…
View article: Charting the Impact of Maternal Antibodies and Repeat Exposures on Sapovirus Immunity in Early Childhood From a Nicaraguan Birth Cohort
Charting the Impact of Maternal Antibodies and Repeat Exposures on Sapovirus Immunity in Early Childhood From a Nicaraguan Birth Cohort Open
Background Sapovirus is an important cause of acute gastroenteritis in childhood. While vaccines against sapovirus may reduce gastroenteritis burden, a major challenge to their development is a lack of information about natural immunity. M…
View article: Emergence of Novel Norovirus GII.4 Variant
Emergence of Novel Norovirus GII.4 Variant Open
We detected a novel GII.4 variant with an amino acid insertion at the start of epitope A in viral protein 1 of noroviruses from the United States, Gabon, South Africa, and the United Kingdom collected during 2017-2022. Early identification…
View article: Infant antibody and B-cell responses following confirmed pediatric GII.17 norovirus infections functionally distinguish GII.17 genetic clusters
Infant antibody and B-cell responses following confirmed pediatric GII.17 norovirus infections functionally distinguish GII.17 genetic clusters Open
Genogroup II (GII) noroviruses are a major cause of diarrheal disease burden in children in both high- and low-income countries. GII.17 noroviruses are composed of distinct genetic clusters (I, II, IIIa, and IIIb) and have shown potential …
View article: Infant antibody and B-cell responses following confirmed pediatric GII.17 norovirus infections functionally distinguish GII.17 genetic clusters
Infant antibody and B-cell responses following confirmed pediatric GII.17 norovirus infections functionally distinguish GII.17 genetic clusters Open
Genogroup II (GII) noroviruses are a major cause of diarrheal disease burden in children in both high- and low-income countries. GII.17 noroviruses are composed of distinct genetic clusters (I, II, IIIa, and IIIb) and have shown potential …
View article: Issue Information
Issue Information Open
10,224 (Rest of World), €6,625 (Europe), £5,
View article: Emergent variant modeling of the serological repertoire to norovirus in young children
Emergent variant modeling of the serological repertoire to norovirus in young children Open
View article: Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later
Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later Open
The U.S. Food and Drug Administration only gave emergency-use-authorization of the BNT162b2 and the mRNA-1273 SARS-CoV-2 vaccines for infants 6 months and older in June 2022. Yet, questions regarding the durability of vaccine efficacy, esp…
View article: Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later
Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later Open
The U.S. Food and Drug Administration only gave emergency use authorization of the BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines for infants 6 months and older in June 2022. Yet questions regarding the durability of vaccine efficacy, especial…
View article: Immune Imprinting Drives Human Norovirus Potential for Global Spread
Immune Imprinting Drives Human Norovirus Potential for Global Spread Open
Understanding the complex interactions between virus and host that drive new strain evolution is key to predicting the emergence potential of variants and informing vaccine development. Under our hypothesis, future dominant human norovirus…
View article: Norovirus Infection in Young Nicaraguan Children Induces Durable and Genotype-Specific Antibody Immunity
Norovirus Infection in Young Nicaraguan Children Induces Durable and Genotype-Specific Antibody Immunity Open
There are significant challenges to the development of a pediatric norovirus vaccine, mainly due to the antigenic diversity among strains infecting young children. Characterizing human norovirus serotypes and understanding norovirus immuni…
View article: Immune Imprinting Drives Human Norovirus Potential for Global Spread
Immune Imprinting Drives Human Norovirus Potential for Global Spread Open
In our model, preepidemic human norovirus variants harbor genetic diversification that translates into novel antigenic features without compromising viral fitness. Through surveillance, we identified two viruses fitting this profile, formi…
View article: Breadth and Dynamics of Human Norovirus-Specific Antibodies in the First Year of Life
Breadth and Dynamics of Human Norovirus-Specific Antibodies in the First Year of Life Open
We measured antibody binding to diverse norovirus virus-like particles over 12 months in 16 children. All had maternal antibodies at 2 months, with estimated lowest levels at 5 months of age. Antibody increases after 3 months suggested nat…
View article: Preexisting Heterotypic Ligand-blocking Antibody Does Not Protect Against Genogroup II Norovirus Episodes in Young Children
Preexisting Heterotypic Ligand-blocking Antibody Does Not Protect Against Genogroup II Norovirus Episodes in Young Children Open
A birth cohort design was used to understand whether heterotypic ligand-blocking norovirus antibodies provide cross-protection within the GII genogroup. We found that almost one-half of children who experienced a norovirus GII episode had …
View article: Antigenic Site Immunodominance Redirection Following Repeat Variant Exposure
Antigenic Site Immunodominance Redirection Following Repeat Variant Exposure Open
Human norovirus is a leading cause of acute gastroenteritis, driven by antigenic variants within the GII.4 genotype. Antibody responses to GII.4 vaccination in adults are shaped by immune memory. How children without extensive immune memor…
View article: Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum
Dose-Response of a Norovirus GII.2 Controlled Human Challenge Model Inoculum Open
Background Genogroup II noroviruses are the most common cause of acute infectious gastroenteritis. We evaluated the use of a new GII.2 inoculum in a human challenge. Methods Forty-four healthy adults (36 secretor-positive and 8 secretor-ne…
View article: Predicted norovirus resurgence in 2021–2022 due to the relaxation of nonpharmaceutical interventions associated with COVID-19 restrictions in England: a mathematical modeling study
Predicted norovirus resurgence in 2021–2022 due to the relaxation of nonpharmaceutical interventions associated with COVID-19 restrictions in England: a mathematical modeling study Open
Background To reduce the coronavirus disease burden in England, along with many other countries, the government implemented a package of non-pharmaceutical interventions (NPIs) that have also impacted other transmissible infectious disease…
View article: Serological Humoral Immunity Following Natural Infection of Children with High Burden Gastrointestinal Viruses
Serological Humoral Immunity Following Natural Infection of Children with High Burden Gastrointestinal Viruses Open
Acute gastroenteritis (AGE) is a major cause of morbidity and mortality worldwide, resulting in an estimated 440,571 deaths of children under age 5 annually. Rotavirus, norovirus, and sapovirus are leading causes of childhood AGE. A succes…
View article: Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice Open
The emergence of SARS-CoV in 2003 and SARS-CoV-2 in 2019 highlights the need to develop universal vaccination strategies against the broader Sarbecovirus subgenus. Using chimeric spike designs, we demonstrate protection against challenge f…
View article: Predicted Norovirus Resurgence in 2021-2022 Due to the Relaxation of Nonpharmaceutical Interventions Associated with COVID-19 Restrictions in England: A Mathematical Modelling Study
Predicted Norovirus Resurgence in 2021-2022 Due to the Relaxation of Nonpharmaceutical Interventions Associated with COVID-19 Restrictions in England: A Mathematical Modelling Study Open
Background To reduce the coronavirus disease burden in England, along with many other countries, the Government implemented a package of non-pharmaceutical interventions (NPIs) that have also impacted other transmissible infectious disease…
View article: Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice Open
A broad defense against SARS-like viruses Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the third coronavirus that has emerged as a serious human pathogen in the past 20 years. Treatment strategies that are broadly protec…
View article: SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques
SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques Open
SARS-CoV-2 vaccines are well tolerated and highly immunogenic in infant rhesus macaques.
View article: Secretor Status Strongly Influences the Incidence of Symptomatic Norovirus Infection in a Genotype-Dependent Manner in a Nicaraguan Birth Cohort
Secretor Status Strongly Influences the Incidence of Symptomatic Norovirus Infection in a Genotype-Dependent Manner in a Nicaraguan Birth Cohort Open
Background The role of histo-blood group on the burden and severity of norovirus gastroenteritis in young infants has not been well documented. Methods Norovirus gastroenteritis was assessed in 443 Nicaraguan children followed from birth u…
View article: A luciferase-based approach for measuring HBGA blockade antibody titers against human norovirus
A luciferase-based approach for measuring HBGA blockade antibody titers against human norovirus Open
View article: SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques
SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques Open
Early life SARS-CoV-2 vaccination has the potential to provide lifelong protection and achieve herd immunity. To evaluate SARS-CoV-2 infant vaccination, we immunized two groups of 8 infant rhesus macaques (RMs) at weeks 0 and 4 with stabil…
View article: Chimeric spike mRNA vaccines protect against Sarbecoviru<i>s</i>challenge in mice
Chimeric spike mRNA vaccines protect against Sarbecoviru<i>s</i>challenge in mice Open
The emergence of SARS-CoV in 2003 and SARS-CoV-2 in 2019 highlights the need to develop universal vaccination strategies against the broader Sarbecovirus subgenus. Using chimeric spike designs, we demonstrate protection against challenge f…
View article: Norovirus-Specific CD8+ T Cell Responses in Human Blood and Tissues
Norovirus-Specific CD8+ T Cell Responses in Human Blood and Tissues Open
View article: Disulfide stabilization of human norovirus GI.1 virus-like particles focuses immune response toward blockade epitopes
Disulfide stabilization of human norovirus GI.1 virus-like particles focuses immune response toward blockade epitopes Open
Human noroviruses are non-enveloped, single-strand RNA viruses that cause pandemic outbreaks of acute gastroenteritis. A bivalent vaccine containing GI.1 and GII.4 virus-like particles (VLPs) has been shown to be safe and highly immunogeni…